Provided by Tiger Trade Technology Pte. Ltd.

Seaport Therapeutics

22.96
-1.7400-7.04%
Post-market: 22.960.00000.00%16:10 EDT
Volume:158.93K
Turnover:3.74M
Market Cap:1.23B
PE:-9.13
High:24.95
Open:24.56
Low:22.63
Close:24.70
52wk High:28.38
52wk Low:14.85
Shares:53.53M
Float Shares:14.16M
Volume Ratio:0.87
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5160
EPS(LYR):-10.0430
ROE:-28.08%
ROA:-18.90%
PB:2.91
PE(LYR):-2.29

Loading ...

Seaport Therapeutics CEO Daphne Zohar Presents at Goldman Sachs Life Sciences Symposium

Reuters
·
Sep 14

Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)

TIPRANKS
·
Sep 10

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo

Reuters
·
Sep 10

PureTech Health: Glyphallo 375 Mg Did not Impair Next-Morning Driving Performance on Day 5

THOMSON REUTERS
·
Sep 10

PureTech Health: Glyphallo was Well-Tolerated, with no Serious Adverse Events Reported

THOMSON REUTERS
·
Sep 10

PureTech Health: to Submit Glyphallo Phase 1 Results to U.S. FDA

THOMSON REUTERS
·
Sep 10

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

MT Newswires Live
·
Sep 09

Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint

TIPRANKS
·
Sep 09

Seaport Therapeutics Says Phase 1 Trial Shows GlyphAllo 375 Mg Does not Impair Next-Morning Driving vs Placebo

Reuters
·
Sep 09

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of Glyphallo™ in Healthy Volunteers

THOMSON REUTERS
·
Sep 09

Seaport Therapeutics - Key Secondary Endpoint Met for 250 Mg Glyphallo on Day 2

THOMSON REUTERS
·
Sep 09

Seaport Therapeutics - Enrolling Buoy-1 Phase 2B Trial for Glyphallo; Topline Data Expected First Half 2027

THOMSON REUTERS
·
Sep 09

Seaport Therapeutics - Glyphallo Well-Tolerated with no Serious Adverse Events Reported

THOMSON REUTERS
·
Sep 09

Seaport Therapeutics - Phase 1 Trial Meets Primary Endpoint for 375 Mg Glyphallo on Day 5

THOMSON REUTERS
·
Sep 09

Seaport Therapeutics Participates in Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Aug 31

Seaport Therapeutics Initiated at Buy by Jones Trading

Dow Jones
·
Aug 26

JonesTrading Initiates Coverage on Seaport Therapeutics With Buy Rating, $32 Price Target

MT Newswires Live
·
Aug 26

Wall Street Analysts Are Bullish on Top NA Picks

TIPRANKS
·
Aug 26

Seaport Therapeutics Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 20